Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib-Sensitive and Resistant K562 Chronic Myeloid Leukemia Cells
| dc.contributor.author | Can, Geylani | |
| dc.contributor.author | Çakır, Zeynep | |
| dc.contributor.author | Kartal, Melis | |
| dc.contributor.author | Gündüz, Ufuk | |
| dc.contributor.author | Baran, Yusuf | |
| dc.date.accessioned | 2017-05-15T13:58:47Z | |
| dc.date.available | 2017-05-15T13:58:47Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | To examine the antiproliferative and apoptotic effects of resveratrol on imatinib-sensitive and imatinib-resistant K562 chronic myeloid leukemia cells. Antiproliferative effects of resveratrol were determined by the 3-Bis[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) cell proliferation assay. Apoptotic effects of resveratrol on sensitive K562 and resistant K562/IMA-3 cells were determined through changes in caspase-3 activity, loss of mitochondrial membrane potential (MMP), and apoptosis by annexin V-(FITC). The concentrations of resveratrol that inhibited cell growth by 50% (IC(50)) were calculated as 85 and 122 μM for K562 and K562/IMA-3 cells, respectively. There were 1.91-, 7.42- and 14.73-fold increases in loss of MMP in K562 cells treated with 10, 50, and 100 μM resveratrol, respectively. The same concentrations of resveratrol resulted in 2.21-, 3.30- and 7.65-fold increases in loss of MMP in K562/IMA-3 cells. Caspase-3 activity increased 1.04-, 2.77- and 4.8-fold in K562 and 1.02-, 1.41- and 3.46-fold in K562/IMA-3 cells in response to the same concentrations of resveratrol, respectively. Apoptosis was induced in 58.7%- and 43.3% of K562 and K562/IMA-3 cells, respectively, in response to 100 μM resveratrol. Taken together these results may suggest potential use of resveratrol in CML, as well as in patients with primary and/or acquired resistance to imatinib. | en_US |
| dc.identifier.citation | Can, G., Çakır, Z., Kartal, M., Gündüz, U. ,and Baran, Y. (2012). Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells. Anticancer research, 32(7), 2673-2678. | en_US |
| dc.identifier.issn | 1791-7530 | |
| dc.identifier.issn | 0250-7005 | |
| dc.identifier.scopus | 2-s2.0-84867130707 | |
| dc.identifier.uri | https://hdl.handle.net/11147/5513 | |
| dc.language.iso | en | en_US |
| dc.publisher | International Institute of Anticancer Research | en_US |
| dc.relation.ispartof | Anticancer Research | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Antineoplastic agent | en_US |
| dc.subject | Chronic myeloid leukemia | en_US |
| dc.subject | Resveratrol | en_US |
| dc.subject | Stilbene derivative | en_US |
| dc.subject | Cell growth | en_US |
| dc.subject | Imatinib | en_US |
| dc.title | Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib-Sensitive and Resistant K562 Chronic Myeloid Leukemia Cells | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Can, Geylani | |
| gdc.author.institutional | Çakır, Zeynep | |
| gdc.author.institutional | Kartal, Melis | |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.author.yokid | 119193 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 2678 | en_US |
| gdc.description.issue | 7 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.startpage | 2673 | en_US |
| gdc.description.volume | 32 | en_US |
| gdc.description.wosquality | Q4 | |
| gdc.identifier.openalex | W2127514222 | |
| gdc.identifier.pmid | 22753725 | |
| gdc.identifier.wos | WOS:000306254300031 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 7.0 | |
| gdc.oaire.influence | 3.0418474E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Caspase 7 | |
| gdc.oaire.keywords | Membrane Potential, Mitochondrial | |
| gdc.oaire.keywords | Dose-Response Relationship, Drug | |
| gdc.oaire.keywords | Chronic myeloid leukemia | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | Cell Growth Processes | |
| gdc.oaire.keywords | Antineoplastic Agents, Phytogenic | |
| gdc.oaire.keywords | Piperazines | |
| gdc.oaire.keywords | Cell growth | |
| gdc.oaire.keywords | Pyrimidines | |
| gdc.oaire.keywords | Antineoplastic agent | |
| gdc.oaire.keywords | Stilbene derivative | |
| gdc.oaire.keywords | Drug Resistance, Neoplasm | |
| gdc.oaire.keywords | Resveratrol | |
| gdc.oaire.keywords | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | |
| gdc.oaire.keywords | Imatinib | |
| gdc.oaire.keywords | Benzamides | |
| gdc.oaire.keywords | Stilbenes | |
| gdc.oaire.keywords | Imatinib Mesylate | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | K562 Cells | |
| gdc.oaire.popularity | 2.9863596E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 1.76099391 | |
| gdc.openalex.normalizedpercentile | 0.83 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 15 | |
| gdc.plumx.mendeley | 11 | |
| gdc.plumx.pubmedcites | 8 | |
| gdc.plumx.scopuscites | 27 | |
| gdc.wos.citedcount | 20 | |
| relation.isAuthorOfPublication.latestForDiscovery | 7bb863bb-9384-4a07-9fbb-b9c1ab7634a3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |
